Objective Costs associated with HPV-related diseases such as cervical dysplasia, cervical
cancer, and genital warts have not been evaluated in Sweden. These costs must be …

Summary Background The WHO Director-General has issued a call for action to eliminate
cervical cancer as a public health problem. To help inform global efforts, we modelled …

AIM: Clinical trials have shown prophylactic human papillomavirus (HPV) vaccines to be
effective against infection and disease. We examined whether HPV vaccination has the …

OBJECTIVE: The study predicts long-term cervical cancer related population health and
economic effects of introducing the HPV-vaccination for 12-year-old girls (and boys) in …

Background Information on human papillomavirus (HPV) type distribution is necessary to
evaluate the potential impact of current and future HPV vaccines. We estimated the relative …

Background Human papillomavirus (HPV) infection has been shown to be a major risk factor
for cervical cancer. Vaccines against HPV-16 and HPV-18 are highly effective in preventing …

Background: Despite screening, cervical cancer (CC) remains a serious health care
problem. Because human papillomavirus (HPV) is the necessary cause of CC, the …

Background Human papillomavirus (HPV) vaccination programmes were first implemented
in several countries worldwide in 2007. We did a systematic review and meta-analysis to …

The impact of human papillomavirus (HPV)-16/18 vaccination on the incidence of infection
and disease can be explored in a range of different models. Here we explore the …

While the benefits of human papillomavirus (HPV) vaccination relating to cervical cancer
prevention have been widely documented, recent published evidence is suggestive of an …